The new data platform has enabled researchers to identify study cohorts and receive tailored, de-identified datasets in days, rather than the months the same request might have taken in the past.
This has already led to the publication of breakthrough findings. A group from Deepmind, Moorfields and Google Health used the platform to create an AI model that can predict the progression of retinal disease at least as well as or better than clinicians, opening a clinical window for potential therapeutic treatments.
Pearse A Keane, Consultant Ophthalmologist at Moorfields Eye Hospital NHS Foundation Trust and Professor of Artificial Medical Intelligence at University College London, explains:
“If you looked at the typical types of medical studies before, in ophthalmology, you’d often see a study with 300 patients regarded as a large study. Now, it’s tens of thousands, or hundreds of thousands, or even millions of patients. It wouldn’t have been possible to do a fraction of the things that we’ve been able to achieve without the help of Softwire.”